Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-AXSPAND: Certolizumab Pegol in nr-axSpA
NCT02552212Phase 3Completed
- Sponsor
- UCB
- Start
- Sep 2015
- Primary completion
- May 2018
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 9
01
Overview
A Phase 3 trial of certolizumab pegol in non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by UCB. Started Sep 2015; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT02552212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02552212.